Analysts' average 12-month price target for Spruce Biosciences is $130.
Get informed when a big investor buys or sells
+ Follow$53.86
3 analysts in the last 4 months
High: $150 | Low: $104
No recommendations in the last 4 months.
Spruce Biosciences (SPRB) currently reports a target price of $130. Use the charts on this page to explore Spruce Biosciences's target price history and peer comparisons.
Analysts' average 12-month price target for Spruce Biosciences is $130, about 133.3% upside from the current share price of $53.86. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.
Start with the current target price of $130, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Spruce Biosciences, and consider following SPRB for alerts when major investors trade the stock.
Spruce Biosciences is classified in the Healthcare sector. On target price, it currently shows $130. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRB with unrelated industries.